Reuters logo
2 个月内
BRIEF-Inovio announces clinical trial collaboration to evaluate t-cell immunotherapy in combination with a PD-l1 checkpoint inhibitor
2017年6月1日 / 中午12点20分 / 2 个月内

BRIEF-Inovio announces clinical trial collaboration to evaluate t-cell immunotherapy in combination with a PD-l1 checkpoint inhibitor

1 分钟阅读

June 1 (Reuters) - Inovio Pharmaceuticals Inc

* Inovio announces clinical trial collaboration to evaluate a novel t-cell immunotherapy in combination with a PD-l1 checkpoint inhibitor

* Inovio Pharmaceuticals Inc - ‍clinical collaboration with Genentech, a member of Roche Group, for advanced bladder cancer​

* Inovio Pharmaceuticals Inc - ‍multi-center open-label trial will be managed by Inovio, and Genentech will supply Atezolizumab​

* Inovio Pharmaceuticals Inc - trial ‍is anticipated to start in 2017 and designed to evaluate safety, immune response and clinical efficacy

* Inovio Pharmaceuticals- ‍majority of patients to be enrolled in trial to have previously received, failed to demonstrate meaningful response to checkpoint inhibitor alone​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below